BRPI0411985A - tratamento da disfunção sexual - Google Patents

tratamento da disfunção sexual

Info

Publication number
BRPI0411985A
BRPI0411985A BRPI0411985-1A BRPI0411985A BRPI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A BR PI0411985 A BRPI0411985 A BR PI0411985A
Authority
BR
Brazil
Prior art keywords
treatment
sexual dysfunction
sexual
dysfunction
disorder
Prior art date
Application number
BRPI0411985-1A
Other languages
English (en)
Inventor
Alasdair Mark Naylor
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0316673A external-priority patent/GB0316673D0/en
Priority claimed from GB0318095A external-priority patent/GB0318095D0/en
Priority claimed from GB0321308A external-priority patent/GB0321308D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0411985A publication Critical patent/BRPI0411985A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TRATAMENTO DA DISFUNçãO SEXUAL". A presente invenção refere-se com a utilização de inibidores de guanosina-3<39>,5<39>-monofosfato cíclico-fosfodiesterase de tipo cinco (PDE5), associados a agonistas de 5HT1a para o tratamento de disfunção sexual, em particular do distúrbio da excitação sexual feminina (FSAD) com distúrbio do desejo sexual hipoativo (HSDD) concomitante.
BRPI0411985-1A 2003-07-16 2004-07-12 tratamento da disfunção sexual BRPI0411985A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0316673A GB0316673D0 (en) 2003-07-16 2003-07-16 Treatment of female sexual dysfunction
GB0318095A GB0318095D0 (en) 2003-08-01 2003-08-01 Treatment of sexual dysfunction
GB0321308A GB0321308D0 (en) 2003-09-11 2003-09-11 Treatment of sexual dysfunction
PCT/IB2004/002286 WO2005007166A1 (en) 2003-07-16 2004-07-12 Treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
BRPI0411985A true BRPI0411985A (pt) 2006-08-29

Family

ID=34084177

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411985-1A BRPI0411985A (pt) 2003-07-16 2004-07-12 tratamento da disfunção sexual

Country Status (7)

Country Link
EP (1) EP1653966A1 (pt)
JP (1) JP2007516949A (pt)
BR (1) BRPI0411985A (pt)
CA (1) CA2532252A1 (pt)
MX (1) MXPA06000623A (pt)
TW (1) TW200505410A (pt)
WO (1) WO2005007166A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
AR048128A1 (es) 2003-12-01 2006-04-05 Akzo Nobel Nv Un tratamiento de la difuncion sexual
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
EP1750766B1 (en) 2004-05-11 2013-07-03 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
MX2008013827A (es) * 2006-05-09 2008-11-10 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2695932A1 (en) 2012-08-08 2014-02-12 Ab Nanol Technologies Oy Grease composition
EP3833341B1 (en) * 2018-08-07 2025-04-02 Ilylt, LLC Compositions for use in treating sexual dysfunction and non therapeutic methods for enhancing sexual response and pleasure
IL292775A (en) * 2019-11-08 2022-07-01 Vella Bioscience Inc preparations containing cannabidiol (cbd) that act peripherally and their use to improve female sexual function or to treat female sexual disorders
EP4665347A1 (en) * 2023-02-14 2025-12-24 Daré Bioscience, Inc. Compositions and methods of treating female sexual dysfunction and female sexual arousal disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055070A1 (en) * 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
GB0106446D0 (en) * 2001-03-15 2001-05-02 Vernalis Res Ltd Chemical compounds
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
MXPA06000623A (es) 2006-04-11
TW200505410A (en) 2005-02-16
EP1653966A1 (en) 2006-05-10
JP2007516949A (ja) 2007-06-28
WO2005007166A1 (en) 2005-01-27
CA2532252A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
BRPI0411985A (pt) tratamento da disfunção sexual
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20085099L (no) Puritonderivativer som HM74A agonister
NO20085257L (no) Purinonderivater som HM74a-agonister
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
PH12014501440A1 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
BR122019021238B8 (pt) uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200870425A1 (ru) Применение агонистов рецептора grp119 для повышения костной массы и для лечения остеопороза и связанной с ними комбинированной терапии
PE20150680A1 (es) Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
EA201491697A1 (ru) Составы агонистов гуанилатциклазы с и способы применения
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
CL2008001074A1 (es) Uso de compuestos de triazol, antagonistas de smo para tratar cancer.

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.